

I. AMENDMENTS TO THE SPECIFICATION

Please amend the Abstract of the specification on page 48 as follows:

Disclosed is a pharmaceutical composition, comprising two analgesic compounds and/or pharmaceutically acceptable salts thereof consisting a combination of a dose of N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide and/or at least one a pharmaceutically acceptable salt thereof and a dose oxycodone and/or at least one a pharmaceutically acceptable salt thereof, said ~~combination~~ two analgesic compounds in an amount sufficient to provide an analgesic effect in a human patient. Also disclosed is a method of effectively treating pain in humans or other mammals, comprising orally administering to the patient a an oral dosage form comprising two analgesic compounds consisting combination of a dose of N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide and/or at least one a pharmaceutically acceptable salt thereof and a dose of oxycodone and/or at least one a pharmaceutically acceptable salt thereof ~~such that the dosing interval of the N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide overlaps with the dosing interval of the oxycodone,~~ said ~~combination~~ two analgesic compounds in an amount sufficient to provide an analgesic effect in a human patient.